Ticker: SGMT

Sagimet Biosciences Inc. (NASDAQ: SGMT) - quick operating & financial snapshot What's happening inside: management is funding aggressive clinical progression - denifanstat advancing toward Phase 3 (positive Phase 2b data and FDA Breakthrough Therapy designation) while a China partner (Ascletis) r...

Sagimet Biosciences Inc. (NASDAQ: SGMT) has recently reported its financial results for the quarter ended March 31, 2025. The company remains in the clinical stage of developing its lead product, denifanstat, a novel fatty acid synthase (FASN) inhibitor targeting conditions such as metabolic dysf...